Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 200 versus PENAPAR VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 200 versus PENAPAR VK.
AUGMENTIN '200' vs PENAPAR-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamases, preventing degradation of amoxicillin.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
One 200 mg amoxicillin/28.5 mg clavulanate chewable tablet every 8 hours for mild to moderate infections; for severe infections, one 400 mg/57 mg tablet every 12 hours or one 200 mg/28.5 mg tablet every 8 hours.
250-500 mg orally every 6 hours; maximum 2 g/day.
None Documented
None Documented
Amoxicillin: ~1 hour in healthy adults, prolonged to 7-20 hours in renal impairment (CrCl <10 mL/min). Clavulanate: ~1 hour, similarly prolonged in renal impairment. The combination's half-life supports twice-daily dosing for most infections.
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion, with the remainder hepatically metabolized and excreted in bile and feces. Clavulanate: ~30-50% excreted unchanged in urine, the rest metabolized and eliminated in bile and feces.
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic